Facility expansion combines biologics and small molecule drug product manufacturing under one roof to accelerate its haematology and oncology pipeline.
BeOne Medicines is investing $300 million to expand its flagship manufacturing and research and development (R&D) centre in New Jersey, US. The decision will support greater production capacity and BeOne’s oncology pipeline.
It brings the firm’s total manufacturing investment in Hopewell to over $1 billion.
The new Princeton West Innovation Campus building in Hopewell will house drug product manufacturing and packaging operations to help build BeOne’s haematology portfolio and pipeline, alongside quality control laboratories.
The expansion at the campus will combine existing biologics production with new small molecule drug product capabilities under one roof, generating approximately 120 new jobs. A new three-story, 145,000ft2 building will be added adjacent to BeOne’s existing Hopewell facilities.
Aaron Rosenberg, Chief Financial Officer, BeOne Medicines, said the firm’s investment “reflects BeOne’s commitment to strengthening US manufacturing and expanding access to innovative medicines for patients with cancer.”
The investment reflects BeOne’s commitment to strengthening US manufacturing and expanding access to innovative medicines for patients with cancer”
Aaron Rosenberg, Chief Financial Officer, BeOne Medicines
This news comes amid US President Trump reporting via social media this week, a future tariff rate of 200 percent for US-imported generic medicines. According to the White House, the decision penalises firms “that decide not to build Plant and Equipment within the stated period of time given to them”.
While the current tariff rate for these medicines is zero, Trump plans to raise the rate to 100 percent for one year starting August 2028, then subsequently to 200 percent.
Only a couple of months ago did he impose a 100 percent tariff on patented branded medicines, under Section 232 of the Trade Expansion Act, months after an initial announcement.
Evonik this month also invested in its US manufacturing capabilities, directing $100 million into its drug substance contract manufacturing site in Lafayette, Indiana.
No comments yet